Pharma License Option Signed
PKAN Logs Retrophin $25M; Autism/Schizo Bid Lies Ahead, Too
By Randy Osborne
Friday, August 16, 2013
With $25 million pledged from a stock sale to institutional investors, rare-disease specialist Retrophin Inc. signed a deal with an unidentified pharma firm for an option to license its autism/schizophrenia drug and said plans for a potentially pivotal trial are on track for RE-021.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.